A Phase 2 interventional study of CFZ533 and Placebo to CFZ533 in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 2, and was the 4th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Italy
Ages 18–100
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.
This is a randomized, subject and investigator-blinded, placebo-controlled, multi-center and parallel-group non-confirmatory study to assess the efficacy, safety and tolerability of five investigational drugs, CFZ533 (iscalimab), LYS006, MAS825, LOU064 (remibrutinib) and VAY736 (ianalumab) in subjects with moderate to severe hidradenitis suppurativa.
All participants from Cohorts A, B and C had planned a 16-week treatment period and 12-week safety follow up period. All participants for Cohort D had planned a 16-week treatment period and 4-week safety follow up period.
All participants for Cohort E had planned a 16-week treatment period and a mandatory 16-week safety follow-up period, plus a conditional follow-up period for up to 84 weeks for a total maximum follow up period of 2 years. Cohorts A-D are completed and Cohort E is ongoing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
Drug: CFZ533
LYS006 20 mg administered orally twice per day until Week 16.
Drug: LYS006
Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
Drug: Placebo to CFZ533
Placebo administered orally twice per day until Week 16.
Drug: Placebo to LYS006
MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
Drug: MAS825
Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
Drug: Placebo to MAS825
LOU064 25 mg administered orally twice per day until Week 16.
Drug: LOU064 25mg
LOU064 100 mg administered orally twice per day until Week 16.
Drug: LOU064 100mg
Placebo administered orally twice per day until Week 16.
Drug: Placebo to LOU064
VAY736 300 mg administered s.c every 4 weeks until Week 13.
Drug: VAY736
Placebo administered s.c every 4 weeks until Week 13.
Drug: Placebo to VAY736
CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
Also known as: iscalimab
Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
LYS006 20 mg administered orally twice per day until Week 16.
Placebo administered orally twice per day until Week 16.
MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
LOU064 25 mg administered orally twice per day until Week 16.
Also known as: remibrutinib
LOU064 100 mg administered orally twice per day until Week 16.
Also known as: remibrutinib
Placebo administered orally twice per day until Week 16.
VAY736 300 mg administered s.c every 4 weeks until Week 13.
Also known as: ianalumab
Placebo administered s.c every 4 weeks until Week 13.
Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)
sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and pooled placebo groups were computed respectively. At the time of the statistical comparison for cohorts A, B, and C, the placebo data for cohorts D and E were incomplete and therefore excluded. Similarly, during the comparison for cohort D, the placebo data for cohort E was still pending and was not included.
Time frame: Baseline, Week 16
Participants took part in 36 investigative sites in 11 countries.
| Milestone | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 | Cohort E - VAY736 300 mg | Cohort E - Placebo to VAY736 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 29 | 16 | 27 | 13 | 33 | 10 | 33 | 33 | 11 | 32 | 11 |
| Completed | 25 | 12 | 20 | 9 | 29 | 9 | 29 | 26 | 8 | 23 | 10 |
| Not completed | 4 | 4 | 7 | 4 | 4 | 1 | 4 | 7 | 3 | 9 | 1 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 4 | 1 | 2 | 1 | 4 | 3 | 2 | 8 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Milestone | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 | Cohort E - VAY736 300 mg | Cohort E - Placebo to VAY736 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 26 | 12 | 21 | 9 | 28 | 9 | 30 | 27 | 8 | 23 | 10 |
| Completed | 24 | 11 | 19 | 8 | 26 | 7 | 30 | 25 | 8 | 0 | 1 |
| Not completed | 2 | 1 | 2 | 1 | 2 | 2 | 0 | 2 | 0 | 23 | 9 |
| Withdrew: Follow up ongoing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 9 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 |
sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and pooled placebo groups were computed respectively. At the time of the statistical comparison for cohorts A, B, and C, the placebo data for cohorts D and E were incomplete and therefore excluded. Similarly, during the comparison for cohort D, the placebo data for cohort E was still pending and was not included.
| Participants | Cohort A - CFZ533 600 mg | Cohort B - LYS006 20 mg | Cohort C - MAS825 300 mg | Pooled Placebo (Cohorts A, B and C) | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Pooled Placebo (Cohorts A, B, C and D) | Cohort E - VAY736 300 mg | Pooled Placebo (Cohorts A, B, C, D and E) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR) | 17 | 8 | 15 | 14 | 24 | 16 | 17 | 16 | 23 |
Collected over Cohorts A, B and C: 28 weeks including 12 weeks follow up period. Cohort D: 20 weeks including 4 weeks follow up period. Cohort E (ongoing): up to 116 weeks including 100 weeks follow up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A - CFZ533 600 mg | 0/29 (0%) | 4/29 (13.8%) | 23/29 (79.3%) |
| Cohort B - LYS006 20 mg | 0/27 (0%) | 2/27 (7.4%) | 19/27 (70.4%) |
| Cohort C - MAS825 300 mg | 0/33 (0%) | 1/33 (3%) | 22/33 (66.7%) |
| Cohort D - LOU064 25 mg | 0/33 (0%) | 1/33 (3%) | 26/33 (78.8%) |
| Cohort D - LOU064 100 mg | 0/33 (0%) | 1/33 (3%) | 15/33 (45.5%) |
| Cohort E - VAY736 300 mg | 0/32 (0%) | 1/32 (3.1%) | 18/32 (56.3%) |
| Pooled Placebo (Cohorts A, B, C, D and E) | 0/61 (0%) | 1/61 (1.6%) | 38/61 (62.3%) |
| Total | 0/248 (0%) | 11/248 (4.4%) | 161/248 (64.9%) |
| Event | Cohort A - CFZ533 600 mg | Cohort B - LYS006 20 mg | Cohort C - MAS825 300 mg | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort E - VAY736 300 mg | Pooled Placebo (Cohorts A, B, C, D and E) | Total |
|---|---|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/29 | 1/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Alcohol withdrawal syndromePsychiatric disorders | 0/29 | 1/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Abscess limbInfections and infestations | 1/29 | 0/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Genital abscessInfections and infestations | 1/29 | 0/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Ovarian cystReproductive system and breast disorders | 1/29 | 0/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Testicular torsionReproductive system and breast disorders | 1/29 | 0/27 | 0/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| ColitisGastrointestinal disorders | 0/29 | 0/27 | 0/33 | 0/33 | 0/33 | 1/32 | 0/61 | 1/248 |
| Pancreatitis acuteGastrointestinal disorders | 0/29 | 0/27 | 0/33 | 1/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| DepressionPsychiatric disorders | 0/29 | 0/27 | 1/33 | 0/33 | 0/33 | 0/32 | 0/61 | 1/248 |
| Hypertensive crisisVascular disorders | 0/29 | 0/27 | 0/33 | 0/33 | 1/33 | 0/32 | 0/61 | 1/248 |
| Event | Cohort A - CFZ533 600 mg | Cohort B - LYS006 20 mg | Cohort C - MAS825 300 mg | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort E - VAY736 300 mg | Pooled Placebo (Cohorts A, B, C, D and E) | Total |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 3/29 | 1/27 | 8/33 | 2/33 | 2/33 | 0/32 | 3/61 | 19/248 |
| NasopharyngitisInfections and infestations | 1/29 | 4/27 | 3/33 | 7/33 | 2/33 | 4/32 | 3/61 | 24/248 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/29 | 2/27 | 5/33 | 1/33 | 0/33 | 6/32 | 8/61 | 22/248 |
| Injection related reactionInjury, poisoning and procedural complications | 0/29 | 0/27 | 0/33 | 0/33 | 0/33 | 5/32 | 1/61 | 6/248 |
| HeadacheNervous system disorders | 2/29 | 4/27 | 5/33 | 4/33 | 0/33 | 1/32 | 6/61 | 22/248 |
| FatigueGeneral disorders and administration site conditions | 1/29 | 4/27 | 3/33 | 3/33 | 1/33 | 0/32 | 4/61 | 16/248 |
| PyrexiaGeneral disorders and administration site conditions | 1/29 | 3/27 | 1/33 | 2/33 | 0/33 | 1/32 | 4/61 | 12/248 |
| Urine albumin/creatinine ratio increasedInvestigations | 2/29 | 3/27 | 1/33 | 1/33 | 1/33 | 0/32 | 2/61 | 10/248 |
| AstheniaGeneral disorders and administration site conditions | 3/29 | 0/27 | 2/33 | 2/33 | 0/33 | 0/32 | 4/61 | 11/248 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/29 | 1/27 | 0/33 | 1/33 | 0/33 | 0/32 | 2/61 | 7/248 |
| Age, Continuous(years) | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 | Cohort E - VAY736 300 mg | Cohort E - Placebo to VAY736 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 38.0 ± 8.68 | 41.4 ± 9.54 | 36.4 ± 9.62 | 36.5 ± 13.29 | 39.5 ± 8.22 | 36.9 ± 10.26 | 35.6 ± 10.84 | 35.3 ± 10.99 | 44.1 ± 7.83 | 34.6 ± 8.35 | 33.1 ± 11.26 | 37.0 ± 9.94 |
| Sex: Female, Male(Participants) | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 | Cohort E - VAY736 300 mg | Cohort E - Placebo to VAY736 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 16 | 10 | 17 | 7 | 19 | 3 | 18 | 20 | 3 | 17 | 4 | 134 |
| Male | 13 | 6 | 10 | 6 | 14 | 7 | 15 | 13 | 8 | 15 | 7 | 114 |
| Race/Ethnicity, Customized(Participants) | Cohort A - CFZ533 600 mg | Cohort A - Placebo to CFZ533 | Cohort B - LYS006 20 mg | Cohort B - Placebo to LYS006 | Cohort C - MAS825 300 mg | Cohort C - Placebo to MAS825 | Cohort D - LOU064 25 mg | Cohort D - LOU064 100 mg | Cohort D - Placebo to LOU064 | Cohort E - VAY736 300 mg | Cohort E - Placebo to VAY736 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian — Asian | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 |
| Asian — Black Or African American | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 5 | 1 | 13 |
| Asian — Other | 1 | 0 | 1 | 0 | 5 | 0 | 2 | 0 | 0 | 0 | 0 | 9 |
| Asian — Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian — White | 26 | 15 | 24 | 13 | 26 | 10 | 30 | 31 | 10 | 26 | 10 | 221 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2019 to primary completion in Dec 2024, 69 months.
Results were first posted in Feb 2026, 1 year 2 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 69 months is above that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iscalimab · LYS-006 · Arumakimig · Remibrutinib · Ianalumab